Investigational Drug Information for Torcetrapib
✉ Email this page to a colleague
What is the development status for investigational drug Torcetrapib?
Torcetrapib is an investigational drug.
There have been 17 clinical trials for Torcetrapib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Hyperlipidemias, Hyperlipoproteinemias, and Hypercholesterolemia. The leading clinical trial sponsors are Pfizer, Abbott, and University of Utah.
Summary for Torcetrapib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,470 |
| WIPO Patent Applications | 1,389 |
| Japanese Patent Applications | 906 |
| Clinical Trial Progress | Phase 3 (2009-11-01) |
| Vendors | 68 |
Recent Clinical Trials for Torcetrapib
| Title | Sponsor | Phase |
|---|---|---|
| A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1/Phase 2 |
| A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels | PharmaNet | Phase 2 |
| A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels | Dr. Reddy's Laboratories Limited | Phase 2 |
Clinical Trial Summary for Torcetrapib
Top disease conditions for Torcetrapib
Top clinical trial sponsors for Torcetrapib
US Patents for Torcetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
